Skip to main content
Erschienen in:

20.01.2021 | original article

Clinical pharmacist interventions in cardiovascular disease pharmacotherapy in elderly patients on excessive polypharmacy

A retrospective pre-post observational multicentric study

verfasst von: Assistant Professor Matej Stuhec, M.Pharm., Ph.D., Ines Flegar, M.Pharm., Erika Zelko, M.D., Ph.D., Alenka Kovačič, M.Pharm., Ph.D., Valerija Zabavnik, M.Pharm.

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2021

Einloggen, um Zugang zu erhalten

Summary

Background

Cardiovascular diseases (CVD) are often treated with excessive polypharmacy (10 or more medications) in primary care, and these patients are mostly excluded from trials. Collaborative care, including clinical pharmacists (CP), is one of the possible approaches to address these problems; however, it has not been studied yet in this part of Europe. Hence, the main aim of the study was to determine how CP interventions in a medical review form (MR) can have an impact on the pharmacotherapy in patients on excessive polypharmacy with CVD (number of medications, potential drug-drug interactions of type X—pXDDI, potentially inappropriate medications in the elderly—PIM and treatment guidelines adherence).

Methods

This retrospective, observational pre-post multicentric study included elderly patients with CVDs aged 65 years or above, treated with 10 or more medications concomitantly (excessive polypharmacy) in Slovenian primary care (2012–2014). The MR provided by CPs included drug-related problems and potential pXDDIs, as well as PIMs. The pXDDIs were determined with Lexicomp Online. The German Priscus lists was used to determine PIMs. A binary logistic regression model was chosen to examine the influence of independent variables on the dependent variable (treatment guidelines adherence).

Results

In this study 243 patients were included and 980 interventions were proposed in the MR form of which 479 (48.9%) were accepted by the general practitioners (GP). The CPs proposed 320 interventions in CVDs treatment, of which 140 were accepted by the GPs (43.8%). The acceptance of the CPs’ recommendations reduced the number of medications by 7.3% (from 13.1 to 12.1 per patient; p < 0.05), the number of pXDDIs by 47.8% (from 40 to 12 patients; p < 0.05), the total of prescribed PIMs by 26.6% (p = 0.752) and adherence to arterial hypertension treatment guidelines was improved (p < 0.05).

Conclusion

CPs’ interventions significantly improved the quality of pharmacotherapy prescribing by reducing the total number of medications and pXDDIs and led to better hypertension treatment guidelines adherence.
Literatur
1.
Zurück zum Zitat Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.CrossRef Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.CrossRef
2.
Zurück zum Zitat Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.PubMed Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.PubMed
3.
Zurück zum Zitat Kos Kerec M, Vovk T. Zakaj je lahko učinek zdravil pri starostnikih drugačen? 10101010. 2017;61:107–14. Kos Kerec M, Vovk T. Zakaj je lahko učinek zdravil pri starostnikih drugačen? 10101010. 2017;61:107–14.
4.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Guidelines for the managemant of arterial hypertension. Eur Heart J. 2013;34(28):2159–219.CrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Guidelines for the managemant of arterial hypertension. Eur Heart J. 2013;34(28):2159–219.CrossRef
5.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31:1925–38.CrossRef Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31:1925–38.CrossRef
6.
Zurück zum Zitat Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.CrossRef Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.CrossRef
7.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRef
8.
Zurück zum Zitat Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–59.CrossRef Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–59.CrossRef
9.
Zurück zum Zitat Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart Journal. 2016;37:2893–962.CrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart Journal. 2016;37:2893–962.CrossRef
10.
Zurück zum Zitat Verbič Dobravc M. Atrijska fibrilacija in antitrombotiki. Farm Vestn. 2013;64:18–24. Verbič Dobravc M. Atrijska fibrilacija in antitrombotiki. Farm Vestn. 2013;64:18–24.
11.
Zurück zum Zitat Pretnar Oblak J, Cvetojević Z. Ishemična možganska kap-posebnosti pri zdravljenju starostnikov. Farm Vestn. 2017;68:129–35. Pretnar Oblak J, Cvetojević Z. Ishemična možganska kap-posebnosti pri zdravljenju starostnikov. Farm Vestn. 2017;68:129–35.
12.
Zurück zum Zitat Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74.CrossRef Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74.CrossRef
13.
Zurück zum Zitat Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.CrossRef Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.CrossRef
14.
Zurück zum Zitat Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19:118.CrossRef Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19:118.CrossRef
15.
Zurück zum Zitat Barragan NC, DeFosset AR, Torres J, Kuo T. Pharmacist-driven strategies for hypertension management in Los Angeles: a community and stakeholder needs assessment, 2014–2015. Prev Chronic Dis. 2017;14:E54.CrossRef Barragan NC, DeFosset AR, Torres J, Kuo T. Pharmacist-driven strategies for hypertension management in Los Angeles: a community and stakeholder needs assessment, 2014–2015. Prev Chronic Dis. 2017;14:E54.CrossRef
16.
Zurück zum Zitat Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Lang M, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36:1244–54.CrossRef Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Lang M, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36:1244–54.CrossRef
17.
Zurück zum Zitat Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26:399–406.CrossRef Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26:399–406.CrossRef
18.
Zurück zum Zitat Marušič Premuš A. Farmakoterapijski pregledi v bolnišnicah in v ambulantah—izkušnje in evalvacija dela. Pharmacotherapy reviews in hospitals and at an outpatient clinic = experience and evaluation of work. Farm Vestn. 2014;65:187–90. Marušič Premuš A. Farmakoterapijski pregledi v bolnišnicah in v ambulantah—izkušnje in evalvacija dela. Pharmacotherapy reviews in hospitals and at an outpatient clinic = experience and evaluation of work. Farm Vestn. 2014;65:187–90.
20.
Zurück zum Zitat Kovačič A. Farmakoterapijski pregled in ambulante farmacevta svetovalca v Sloveniji. Farm Vestn. 2018;69:39–43. Kovačič A. Farmakoterapijski pregled in ambulante farmacevta svetovalca v Sloveniji. Farm Vestn. 2018;69:39–43.
21.
Zurück zum Zitat Holt S, Schmiedl S, Thürmann AP. Potentially inappropriate medications in the elderly: the PRISCUS List. Dtsch Arztebl Int. 2010;107:543–51.PubMedPubMedCentral Holt S, Schmiedl S, Thürmann AP. Potentially inappropriate medications in the elderly: the PRISCUS List. Dtsch Arztebl Int. 2010;107:543–51.PubMedPubMedCentral
23.
Zurück zum Zitat Abolbashari M, Macaulay TE, Whayne TF, Mukherjee D, Saha S. Polypharmacy in cardiovascular medicine: problems and promises! Cardiovasc Hematol Agents Med Chem. 2017;15(1):31–9.CrossRef Abolbashari M, Macaulay TE, Whayne TF, Mukherjee D, Saha S. Polypharmacy in cardiovascular medicine: problems and promises! Cardiovasc Hematol Agents Med Chem. 2017;15(1):31–9.CrossRef
24.
Zurück zum Zitat Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.CrossRef Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.CrossRef
25.
Zurück zum Zitat Stuhec M, Serra-Mestres J. Antidepressant drugs for older patients on polypharmacy: a systematic review reveals best evidence for sertraline. Glob Psychiatry. 2018;1:17–24.CrossRef Stuhec M, Serra-Mestres J. Antidepressant drugs for older patients on polypharmacy: a systematic review reveals best evidence for sertraline. Glob Psychiatry. 2018;1:17–24.CrossRef
26.
Zurück zum Zitat Anderson SL, Vande Griend JP. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394–402.CrossRef Anderson SL, Vande Griend JP. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394–402.CrossRef
27.
Zurück zum Zitat Wilson SJ. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.CrossRef Wilson SJ. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.CrossRef
28.
Zurück zum Zitat Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15(1):18.CrossRef Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15(1):18.CrossRef
29.
Zurück zum Zitat Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: a systematic review. Eur Psychiatry. 2017;46:1–15.CrossRef Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: a systematic review. Eur Psychiatry. 2017;46:1–15.CrossRef
30.
Zurück zum Zitat Anderegg MD, Gums TH, Uribe L, MacLaughlin EJ, Hoehns J, Bazaldua OV, et al. Pharmacist intervention for blood pressure control in patients with diabetes and/or chronic kidney disease. Pharmacotherapy. 2018;38(3):309–18.CrossRef Anderegg MD, Gums TH, Uribe L, MacLaughlin EJ, Hoehns J, Bazaldua OV, et al. Pharmacist intervention for blood pressure control in patients with diabetes and/or chronic kidney disease. Pharmacotherapy. 2018;38(3):309–18.CrossRef
31.
Zurück zum Zitat Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRef Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRef
32.
Zurück zum Zitat Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a veterans affairs medical center. Am J Health Syst Pharm. 2002;59:2070–7.CrossRef Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a veterans affairs medical center. Am J Health Syst Pharm. 2002;59:2070–7.CrossRef
34.
Zurück zum Zitat Štuhec M, Gorenc K. Klinično ovrednotenje intervencij farmacevta svetovalca v zdravljenju bolečine v ambulanti zdravstvenega Doma pri starejših bolnikih s polifarmakoterapijo = clinical evaluation of pharmacist consultant interventions in community health Centre in nociceptive and neuropathic pain pharmacotherapy in elderly patients treated with polypharmacy. Farm Vestn. 2018;69:57–64. Štuhec M, Gorenc K. Klinično ovrednotenje intervencij farmacevta svetovalca v zdravljenju bolečine v ambulanti zdravstvenega Doma pri starejših bolnikih s polifarmakoterapijo = clinical evaluation of pharmacist consultant interventions in community health Centre in nociceptive and neuropathic pain pharmacotherapy in elderly patients treated with polypharmacy. Farm Vestn. 2018;69:57–64.
Metadaten
Titel
Clinical pharmacist interventions in cardiovascular disease pharmacotherapy in elderly patients on excessive polypharmacy
A retrospective pre-post observational multicentric study
verfasst von
Assistant Professor Matej Stuhec, M.Pharm., Ph.D.
Ines Flegar, M.Pharm.
Erika Zelko, M.D., Ph.D.
Alenka Kovačič, M.Pharm., Ph.D.
Valerija Zabavnik, M.Pharm.
Publikationsdatum
20.01.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01801-y

Weitere Artikel der Ausgabe 15-16/2021

Wiener klinische Wochenschrift 15-16/2021 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month